MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Abbott Wins Additional Indication for MitraClip

The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.

Abbott Laboratories has received an expanded indication for MitraClip. The Abbott Park, IL-based company’s new indication addresses the secondary form of mitral regurgitation and significantly increases the amount of people with MR able to be treated with MitraClip.

Based on this approval, Abbott said it will now begin discussions with the Center for Medicare and Medicaid Services (CMS) and physician specialty societies to request a revision to the national coverage determination that would expand Medicare coverage to include secondary MR patients.The indication was supported by the results of the COAPT Trial.

Abbott said the COAPT trial was a study of 614 patients with heart failure who had moderate-to-severe or severe secondary MR and were randomly assigned to get either continuation of their optimized medication treatment plus the MitraClip or continuation of their optimized medication treatment only.

The risk of being re-hospitalized for heart failure symptoms was reduced by about 47% in the MitraClip group compared to the control group. In addition, the risk of death within two years was decreased by about 37% in the MitraClip group compared to the control group.In an earnings call last month, Miles White, Abbott’s chairman and CEO, spoke about the new indication’s potential.

“The [indication]would further enhance our leadership position in this large and highly under penetrated disease area and offer the potential to create a new multi-billion-dollar cardiac device market over time,” White, said during an earnings call according to a transcript from Seeking Alpha.

Abbott first gained FDA approval for the MitraClip in 2013, however the device was launched in Europe in 2008. The company obtained the MitraClip through the acquisition of Evalve in 2009.

The new indication comes on the heels of Edwards working to boost its own mitral valve repair offerings. Earlier this week, Edward said it invested $35 million in an exclusive right to acquire Corvia Medical and in addition the firm obtained certain assets of Mitralign for an undisclosed sum.

The two companies are also involved in litigation regarding their respective mitral valve technologies. Earlier this year, Abbott said it had filed a lawsuit against Edwards saying the Irvine, CA-based company’s Pascal System for repairing a damaged mitral valve infringes on five patents for the MitraClip.

 

500 characters remaining